Danaher Corporation (NYSE:DHR) Shares Sold by Alapocas Investment Partners Inc.

Key Points

• Alapocas Investment Partners Inc. has reduced its stake in Danaher Corporation by 20.7%, selling 5,348 shares during the first quarter, leaving it with 20,449 shares valued at approximately $4.19 million.
• Insider trading saw Chairman Steven M. Rales sell 1,250,000 shares at an average price of $196.74, marking a 28.70% decrease in his holdings, while corporate insiders own 11.10% of the stock.
• Analyst ratings for Danaher have been mostly positive, with an average rating of "Moderate Buy" and a consensus price target of $247.61, despite recent target reductions by some firms.

Alapocas Investment Partners Inc. decreased its stake in Danaher Corporation (NYSE:DHR - Free Report) by 20.7% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 20,449 shares of the conglomerate's stock after selling 5,348 shares during the quarter. Danaher makes up 2.6% of Alapocas Investment Partners Inc.'s holdings, making the stock its 16th largest position. Alapocas Investment Partners Inc.'s holdings in Danaher were worth $4,192,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also recently modified their holdings of DHR. GHP Investment Advisors Inc. boosted its stake in shares of Danaher by 396.0% during the 1st quarter. GHP Investment Advisors Inc. now owns 124 shares of the conglomerate's stock worth $25,000 after acquiring an additional 99 shares in the last quarter. Heck Capital Advisors LLC acquired a new position in Danaher in the 4th quarter worth about $27,000. Sierra Ocean LLC boosted its position in Danaher by 116.9% during the first quarter. Sierra Ocean LLC now owns 141 shares of the conglomerate's stock worth $29,000 after purchasing an additional 76 shares in the last quarter. Smallwood Wealth Investment Management LLC acquired a new stake in Danaher in the first quarter valued at approximately $31,000. Finally, Dunhill Financial LLC increased its position in shares of Danaher by 68.4% in the first quarter. Dunhill Financial LLC now owns 165 shares of the conglomerate's stock valued at $34,000 after buying an additional 67 shares in the last quarter. Hedge funds and other institutional investors own 79.05% of the company's stock.

Insider Buying and Selling

In related news, Chairman Steven M. Rales sold 1,250,000 shares of the business's stock in a transaction on Monday, May 12th. The stock was sold at an average price of $196.74, for a total transaction of $245,925,000.00. Following the completion of the transaction, the chairman directly owned 3,105,808 shares of the company's stock, valued at $611,036,665.92. The trade was a 28.70% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 11.10% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on DHR shares. Scotiabank raised shares of Danaher from a "sector perform" rating to a "sector outperform" rating and set a $275.00 price target on the stock in a research note on Friday, July 11th. JPMorgan Chase & Co. cut their target price on shares of Danaher from $280.00 to $260.00 and set an "overweight" rating for the company in a research note on Tuesday, April 22nd. Leerink Partners raised their price target on shares of Danaher from $225.00 to $230.00 and gave the company an "outperform" rating in a research note on Wednesday, April 23rd. Barclays reiterated an "overweight" rating and set a $225.00 price objective (up from $215.00) on shares of Danaher in a research note on Tuesday, June 24th. Finally, Deutsche Bank Aktiengesellschaft decreased their target price on Danaher from $240.00 to $235.00 in a research report on Thursday, June 5th. Three investment analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company's stock. According to MarketBeat, Danaher has an average rating of "Moderate Buy" and a consensus price target of $247.61.

Danaher Stock Down 1.9%

DHR stock opened at $195.34 on Thursday. Danaher Corporation has a one year low of $171.00 and a one year high of $279.90. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.22 and a current ratio of 1.62. The firm has a market cap of $139.87 billion, a PE ratio of 41.56, a PEG ratio of 2.77 and a beta of 0.73. The firm's 50 day moving average price is $198.08 and its 200-day moving average price is $201.81.

Danaher (NYSE:DHR - Get Free Report) last posted its earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share for the quarter, beating the consensus estimate of $1.64 by $0.16. Danaher had a net margin of 14.21% and a return on equity of 10.70%. The firm had revenue of $5.94 billion during the quarter, compared to the consensus estimate of $5.83 billion. During the same quarter last year, the firm earned $1.72 EPS. The firm's revenue for the quarter was up 3.4% on a year-over-year basis. On average, equities research analysts anticipate that Danaher Corporation will post 7.63 EPS for the current year.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.